Dataset from A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB076 in Healthy Volunteers and Subjects With Alzheimer's Disease

The primary objective of the study is to evaluate the safety and tolerability of
single-ascending intravenous (IV) infusions of BIIB076 in healthy volunteers and participants
with Alzheimer's disease (AD). A secondary objective of the study for both healthy volunteers
and participants with AD is to assess the serum pharmacokinetic(s) (PK) profile of BIIB076
after single-dose administration. Another secondary objective is to evaluate the
immunogenicity of BIIB076 in serum after single-dose administration.